Up to US$165,000 each, paid over two decades: a US judge approves Bayer’s US$7.25 billion Roundup cancer deal, and Australia’s cases got nothing
A Missouri judge has approved Bayer's US$7.25 billion (about A$11 billion) settlement covering current and future claims that its Roundup weedkiller caused non-Hodgkin lymphoma. Average payments will range from about US$10,000 to US$165,000 and the money will be paid out over roughly two decades. Bayer still denies Roundup causes cancer, and the approval can be appealed.
Live updates
- 12.05pm AWSTLatest
Bayer chief executive Bill Anderson calls the approval a decisive milestone. The company still denies Roundup causes cancer, and the ruling can be appealed.
- Saturday morning AWST
St Louis Circuit Judge Timothy Boyer approves Bayer's US$7.25 billion Roundup class settlement, rejecting objections and finding no collusion.
This page checks for new updates automatically.
Three things to know
- St Louis Circuit Judge Timothy Boyer approved the nationwide class settlement on Friday US time (Saturday morning AWST), rejecting objections to it.
- It covers people already diagnosed with non-Hodgkin lymphoma after Roundup exposure, and people diagnosed within a 16-year window after final approval.
- In Australia, the Federal Court dismissed the lead Roundup class action in July 2024, and a second was discontinued in January 2025, both without compensation.
Bayer has cleared the biggest hurdle yet in a legal fight that has hung over it since 2018: a US judge has approved its US$7.25 billion (about A$11 billion) settlement of current and future claims that Roundup weedkiller caused cancer.
St Louis Circuit Judge Timothy Boyer approved the nationwide class settlement in a Missouri state court on Friday US time (Saturday morning AWST), rejecting a string of objections. He found no evidence of collusion, noting negotiations ran for more than 18 months, and called the deal “among the largest in the history of mass tort personal-injury class action settlements”.
Bayer chief executive Bill Anderson called the approval “a decisive milestone”. The company denies that Roundup or its active ingredient, glyphosate, causes cancer.
Who gets paid, and how much?
The settlement covers two groups. The first is people exposed to Roundup before 17 February 2026 who already have a non-Hodgkin lymphoma diagnosis. The second is people diagnosed with the blood cancer within 16 years of final approval.
Average payments will range from about US$10,000 (A$15,000) to US$165,000 (about A$250,000), depending on how much Roundup a person used, their age at diagnosis and how severe their illness is. Judge Boyer called the average payments fair and adequate.
Bayer will pay the money over about two decades in capped annual instalments, with US$3 billion committed over the first five years for those already diagnosed. US$600 million of the total is set aside for lawyers’ fees.
Why did Bayer settle now?
Because the courts had started to close doors on both sides. In June, the US Supreme Court ruled 7-2 that federal pesticide law blocks failure-to-warn claims in state courts, removing the main argument many plaintiffs had relied on. At the same time, Judge Boyer said there was a risk Bayer would have sought bankruptcy protection if the settlement had been rejected, which could have left claimants waiting years for less.
Bayer has faced about 200,000 Roundup claims since it bought Monsanto, Roundup’s maker, for US$63 billion in 2018. More than 30,000 cases sit in Missouri courts alone, and just over 200 plaintiffs already had trial dates.
What does it mean for Australians?
Nothing in cash. Australia’s Roundup cases ended without compensation: the Federal Court dismissed the McNickle class action in July 2024, finding the evidence did not establish that glyphosate causes non-Hodgkin lymphoma, and the second class action was discontinued in January 2025. Glyphosate remains registered for use in Australia and is one of the most widely used weedkillers on Australian farms.
In the US, glyphosate has already been removed from new versions of Roundup sold for home gardens.
Is it over?
Not quite. The approval can be appealed, and some plaintiffs’ lawyers oppose the deal.
VNN will update this story as more is confirmed.
How we got here
The key moments that brought this story into focus. Open any moment for detail.
2018Bayer buys Monsanto
Bayer pays US$63 billion for Monsanto, Roundup's maker, inheriting thousands of cancer claims.
July 2024Australian case dismissed
The Federal Court dismisses the McNickle Roundup class action.
January 2025Second Australian case ends
Australia's other Roundup class action is discontinued without compensation.
17 February 2026Settlement proposed
Bayer announces the US$7.25 billion class settlement for current and future claims.
June 2026Supreme Court ruling
The US Supreme Court rules 7-2 that federal law blocks failure-to-warn claims in state courts.
20 November 2026Settlement approved
A Missouri judge approves the settlement.
What happens next
Objectors can appeal the approval. Once the settlement is final, claimants in the first group can start the payment process, with US$3 billion due over the first five years, while the 16-year window for new diagnoses begins. Bayer's shares next trade in Frankfurt on Monday 23 November, the first chance for investors to react.
Sources
- VNN
VNN never names people who give us information in confidence. How we protect sources and tips.
That is the story in a minute. For the evidence, context and what happens next, switch to the full story.
We are reporting this as it happens. Details may change.
Weather today
Saturday 21 November
Perth
Cool with a passing shower · 36% rain
19°16°
A cool, showery Saturday for Perth while Adelaide warms to 28; Singapore stays steamy and wet, and London wakes to a 2-degree start.
- Sydney28°18°
- Melbourne24°17°
- Brisbane25°19°
- Adelaide28°15°
- Auckland18°12°
- Singapore29°25°
More cities (13)
- Tokyo13°6°
- Hong Kong21°14°
- Mumbai30°20°
- Dubai30°21°
- Nairobi24°16°
- Lagos32°26°
- Johannesburg26°19°
- London8°2°
- Paris11°7°
- New York15°8°
- Los Angeles18°10°
- Toronto10°5°
- Sao Paulo32°21°
Highs and lows in °C, local time.
Breaking now
Live deskDeveloping stories
Live deskMost read this week
For subscribers
Read every subscriber story in full, on any device. Premium reports are sold separately.
Secure payment · Cancel anytime · Subscribers sign in
Markets
Stocks
- Alphabet (GOOGL)Nasdaq265.29 USDdown -2.70%
- Amazon (AMZN)Nasdaq246.82 USDdown -4.10%
- Apple (AAPL)Nasdaq342.56 USDdown -1.90%
- ASX 200ASX8,730down -1.04%
- Berkshire Hathaway (BRK.B)NYSE570.00 USDdown -0.36%
- BHP Group (BHP)ASX51.40 AUDdown -1.80%
Currencies
- AUD/EURForex0.607100 EURdown -0.31%
- AUD/GBPForex0.508500 GBPup +0.02%
- AUD/JPYForex106.1100 JPYdown -0.41%
- AUD/NZDForex1.212700 NZDdown -0.18%
- AUD/USDForex0.666600 USDdown -0.16%
- BTC/USDCrypto58,970.00 USDdown -5.21%
As at 21 Nov 2026, 6:40 am GMT+0800. Entered by VNN. Not financial advice.
For you
Follow the topics you care about and save stories with the bookmark. They gather here, on this device only.
Saved on this device only. Nothing is sent to VNN.
Help keep the lights on.
Independent news costs money to make and nothing to read. Chip in and keep it that way.
ContributeFrom A$5 a month · Cancel anytimeThe daily briefing
Start informed.
The essential headlines, the useful context and what to watch next, in your inbox each morning.







Comments
0 commentsCommunity rules
To read and join the conversation, please agree to our rules.
You have agreed to the community rules.
No comments yet. Start the conversation.